Jiong Lan

Founder at Genfleet Therapeutics (Shanghai), Inc.

Commercial Services

Profile

Jiong Lan is the founder of Genfleet Therapeutics (Shanghai), Inc. He holds the title of Chief Executive Director & Director since the company's founding in 2017.

Jiong Lan active positions

Companies	Position	Start
Genfleet Therapeutics (Shanghai), Inc. Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017.	Founder	21/08/2017

All active positions of Jiong Lan

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jiong Lan's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Genfleet Therapeutics (Shanghai), Inc. Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017.	Commercial Services